F S&P 500
5,535.50 +14.00 (+0.25%) F Dow Jones
39,515.00 +46.00 (+0.12%) F Nasdaq
19,991.50 +64.25 (+0.32%) E-mini Russell 2000 Index Futur
2,073.90 +8.90 (+0.43%) Petróleo
81.95 +0.41 (+0.50%) Oro
2,331.70 -7.90 (-0.34%)
Carmat SA (CKMTF)
Carmat SA
36, avenue de l'Europe
Immeuble l'Etendard
Vélizy-Villacoublay 78140
France
33 1 39 45 64 50
https://www.carmatsa.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 182
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Stephane Piat | CEO & Director | 834.12k | N/D | 1971 |
| Ms. Pascale d'Arbonneau | CFO & Head of investor relations | N/D | N/D | N/D |
| Ms. Raouia Bouyanzer | Human Resources Director | N/D | N/D | N/D |
| Dr. Petrus Jansen | Chief Medical Officer | N/D | N/D | N/D |
Descripción
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Gestión corporativa
La calificación ISS Governance QuickScore de Carmat SA a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
